SEATTLE, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the upcoming 43rd Annual Cowen Health Care Conference.
Nautilus’ management is scheduled to participate in a fireside chat on Monday, March 6th at 11:50 a.m. Pacific Time / 2:50 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the company’s website on the “Investors” section of the company website at: www.nautilus.bio.
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle and its research and development headquarters in the San Francisco Bay Area, Nautilus is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.
Media Contact
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.81 |
| Daily Change: | 0.02 2.14 |
| Daily Volume: | 105,943 |
| Market Cap: | US$102.560M |
February 27, 2025 October 29, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
